{
    "nct_id": "NCT03785925",
    "official_title": "A Phase 2, Single-Arm Study of Bempegaldesleukin (NKTR-214) in Combination With Nivolumab in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients",
    "inclusion_criteria": "* Provide written, informed consent to participate in the study and follow the study procedures\n* Eastern Cooperative Oncology Group (ECOG) performance status of â‰¤ 2\n* Measurable disease per RECIST 1.1 criteria\n* Histologically or cytologically documented inoperable, locally advanced or metastatic urothelial cell carcinoma (also termed TCC)\n* Fresh biopsy or archival tissue\n* No prior systemic chemotherapy or investigational agent for inoperable locally advanced or mUC\n* Ineligible for cisplatin\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients who have an active, known or suspected autoimmune disease\n* Patients must not have received prior IL-2 therapy\n* Prior treatment with an anti PD-1, anti PD-L1, or anti cytotoxic T lymphocyte associated protein 4 (anti CTLA-4) antibody, agents that target IL-2 pathway, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways\n* Patients with hypertension must be on a stable antihypertensive regimen for the 14 days prior to Cycle 1 Day 1\n\nAdditional protocol-defined inclusion/exclusion criteria applied",
    "miscellaneous_criteria": "Key"
}